Assessment of Bullying in Children

Description

The specific aims of this study are: - To determine the prevalence of bullying in children who present to the ED with behavioral symptoms - To assess mental health diagnoses and their relationship to type, severity and frequency of bullying behaviors, as well as demographic and psychosocial correlates (socioeconomic status, stress and support) and their relationship to type, severity and frequency of bullying (bullies versus victims). - To explore the attitudes, values, triggering events and potential solutions using qualitative methods - To gain greater insight into the patient experience and perceptions of the bullying events

Study Start Date

September 2011

Estimated Completion Date

June 2016

Interventions

No interventions cited

Specialties

  • Pediatrics: Child/Adolescent Psych
  • Psychiatry: Child/Adolescent Psych,Other Psychiatry

MeSH Terms

  • Bullying
  • Problematic Behavior in Children

Study ID

New York City Health and Hospitals Corporation -- 10-027

Status

Unknown

Trial ID

NCT01439763

Study Type

Observational

Trial Phase

N/A

Enrollment Quota

80

Sponsor

New York City Health and Hospitals Corporation

Inclusion Criteria

  • Children with psychiatric or behavioral problem(s) age 8-18 years referred from the school to the ED
  • Parents willing to provide informed consent and child providing assent

Exclusion Criteria

  • Actively violent behavior
  • Child abuse
  • Parents or children refuse to participate

Gender

Both

Ages

8 Years to 18 Years

Accepts Healthy Volunteers

No

Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Lincoln Medical Mental Health Center - Bronx, New York 44.6 miles Muhammad Waseem MD 718-579-6010 Muhammad.waseem@nychhc.org

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.